Skip to main content

Table 1 Status of *lymphoblasts (MRD) in ALL patients at various stages of treatment under MCP841 protocol during a two-year longitudinal follow-up study.

From: Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study

1Weeks Of Treatment

Phases Of Treatment

2Disease Status

3B-ALL (OAcSGP+CD10+CD19+)

3B-ALL (OAcSGP+CD34 +CD19+)

3T-ALL (OAcSGP+CD7+CD3+)

   

PB

BM

PB

BM

PB

BM

# 0

Induction 1

Diagnosis

52 (63.97 ± 9.37)

52 (77.61 ± 6.96)

23 (54.82 ± 6.87)

23 (61.84 ± 9.13)

14 (61.23 ± 6.25)

14 (73.89 ± 7.89)

1

 

CR

49 (0.01 ± 0.005)

NR

18 (0.026 ± 0.018)

NR

11 (0.01 ± 0.001)

NR

2

 

CR

45 (0.02 ± 0.017)

NR

21 (0.032 ± 0.031)

NR

8 (0.03 ± 0.008)

NR

3

 

CR

48 (0.04 ± 0.03)

NR

14 (0.04 ± 0.022)

NR

10 (0.02 ± 0.005)

NR

4

 

CR

31 (0.02 ± 0.009)

NR

19 (0.02 ± 0.017)

NR

9 (0.05 ± 0.02)

NR

#6

Induction 2

CR

40 (0.026 ± 0.016)

41 (0.066 ± 0.028)

22 (0.04 ± 0.027)

17(0.05 ± 0.028)

9 (0.04 ± 0.01)

12 (0.03 ± 0.01)

8

 

CR

44 (0.031 ± 0.015)

NR

17 (0.015 ± 0.01)

NR

12 (0.027 ± 0.01)

NR

#10

Repeat Induction

CR

47 (0.03 ± 0.01)

48 (0.061 ± 0.021)

19 (0.038 ± 0.032)

21 (0.036 ± 0.035)

7 (0.04 ± 0.01)

7 (0.027 ± 0.01)

14

Consolidation

CR

48 (0.02 ± 0.009)

NR

23 (0.03 ± 0.007)

NR

12 (0.02 ± 0.008)

NR

#16

 

CR

46 (0.02 ± 0.008)

44 (0.04 ± 0.025)

13 (0.045 ± 0.029)

20 (0.065 ± 0.017)

11 (0.03 ± 0.021)

9 (0.03 ± 0.018)

18

 

CR

47 (0.04 ± 0.01)

NR

23 (0.036 ± 0.023)

NR

8 (0.03 ± 0.01)

NR

#20

Prior to maintenance

CR

42 (0.018 ± 0.011)

47 (0.058 ± 0.025)

21 (0.04 ± 0.02)

23 (0.054 ± 0.017)

9 (0.02 ± 0.067)

11 (0.03 ± 0.02)

#34

Maintenance 1

CR

43 (0.017 ± 0.008)

46 (0.05 ± 0.027)

21 (0.038 ± 0.026)

19 (0.04 ± 0.01)

11 (0.03 ± 0.01)

11 (0.023 ± 0.01)

#48

Maintenance 2

CR

50 (0.017 ± 0.011)

42 (0.04 ± 0.03)

22(0.032 ± 0.018)

14 (0.063 ± 0.008)

9 (0.023 ± 0.01)

8 (0.03 ± 0.02)

#62

Maintenance 3

CR

43 (0.03 ± 0.02)

44 (0.04 ± 0.01)

23 (0.032 ± 0.018)

21 (0.055 ± 0.015)

11 (0.047 ± 0.02)

10 (0.03 ± 0.01)

#76

Maintenance 4

CR

49 (0.02 ± 0.01)

45 (0.034 ± 0.008)

22 (0.03 ± 0.02)

19 (0.062 ± 0.022)

6 (0.03 ± 0.01)

10 (0.02 ± 0.01)

#90

Maintenance 5

CR

42 (0.04 ± 0.02)

42 (0.03 ± 0.01)

18 (0.04 ± 0.016)

22 (0.02 ± 0.01)

10 (0.026 ± 0.01)

10 (0.04 ± 0.01)

#104

Maintenance 6

CR

44 (0.02 ± 0.008)

44 (0.027 ± 0.003)

21 (0.02 ± 0.008)

21 (0.034 ± 0.016)

13 (0.026 ± 0.02)

8 (0.03 ± 0.02)

Total number of samples

  

810

495

360

220

180

110

  1. * Lymphoblasts with phenotype of OAcSGP+CD10+CD19+, OAcSGP+CD34+CD19+ or OAcSGP+CD7+CD3+.
  2. 1 The samples are received during treatment under MCP841 protocol; PB is received on each of these weeks from each patient, being 18 times per patient.
  3. # The number of times BM is received from each patient at various stages of treatment, being 11 times per patient.
  4. 2 Diagnosis-newly diagnosed patient prior to treatment. This data has been provided to compare the MRD of the patients at clinical remission CR – Clinical Remission; NR – samples were not received in these weeks.
  5. 3 Template for detection of minimal residual disease (MRD).
  6. Numbers before parenthesis indicate the number of patients arrived at that point of treatment.
  7. Numbers in parenthesis indicate the % of OAcSGP+ lymphoblasts simultaneously expressing two other known CD markers (CD10, CD19 or CD34, CD19 or CD7, CD3) at Diagnosis (prior to treatment, 0 week) and as MRD during CR (during treatment between 1–104 weeks) represented as Mean ± SD;
  8. PB – Peripheral Blood; BM – Bone Marrow.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us